# Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

> **NCT00861705** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 454 (actual)

## Conditions studied

- Male Breast Carcinoma
- Stage IIA Breast Cancer AJCC v6 and v7
- Stage IIB Breast Cancer AJCC v6 and v7
- Stage IIIA Breast Cancer AJCC v7
- Triple-Negative Breast Carcinoma

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Carboplatin
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin Hydrochloride
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT00861705
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07-21
- **Primary completion:** 2014-08-01
- **Final completion:** 2025-09-02
- **Target enrollment:** 454 (ACTUAL)
- **Last updated:** 2025-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00861705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00861705, "Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00861705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*